Wall Street brokerages expect DexCom, Inc. (NASDAQ:DXCM) to report $0.03 earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have issued estimates for DexCom’s earnings, with the lowest EPS estimate coming in at ($0.10) and the highest estimate coming in at $0.13. DexCom reported earnings of ($0.09) per share during the same quarter last year, which indicates a positive year over year growth rate of 133.3%. The firm is expected to report its next earnings results on Tuesday, February 27th.
On average, analysts expect that DexCom will report full year earnings of ($0.61) per share for the current fiscal year, with EPS estimates ranging from ($0.74) to ($0.42). For the next year, analysts expect that the firm will post earnings of ($0.38) per share, with EPS estimates ranging from ($0.69) to $0.06. Zacks’ EPS calculations are an average based on a survey of research analysts that that provide coverage for DexCom.
Several research analysts recently commented on DXCM shares. Jefferies Group reiterated a “buy” rating and issued a $91.00 price target on shares of DexCom in a research note on Thursday, September 28th. Canaccord Genuity reiterated a “buy” rating and issued a $69.00 price target (down previously from $90.00) on shares of DexCom in a research note on Thursday, September 28th. Stephens reiterated a “buy” rating and issued a $70.00 price target (down previously from $83.00) on shares of DexCom in a research note on Thursday, September 28th. Piper Jaffray Companies reissued a “buy” rating and issued a $87.00 price objective on shares of DexCom in a report on Thursday, September 28th. Finally, Leerink Swann reissued a “buy” rating and issued a $57.00 price objective (down from $85.00) on shares of DexCom in a report on Friday, September 29th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. DexCom has an average rating of “Buy” and an average target price of $71.15.
Several large investors have recently bought and sold shares of the company. FMR LLC grew its holdings in shares of DexCom by 9.9% during the second quarter. FMR LLC now owns 10,824,306 shares of the medical device company’s stock valued at $791,799,000 after purchasing an additional 978,898 shares during the last quarter. Janus Henderson Group PLC grew its holdings in DexCom by 29.2% in the 3rd quarter. Janus Henderson Group PLC now owns 8,819,825 shares of the medical device company’s stock worth $431,510,000 after buying an additional 1,991,094 shares in the last quarter. Vanguard Group Inc. grew its holdings in DexCom by 3.4% in the 2nd quarter. Vanguard Group Inc. now owns 6,821,102 shares of the medical device company’s stock worth $498,963,000 after buying an additional 224,808 shares in the last quarter. BlackRock Inc. grew its holdings in DexCom by 5.5% in the 2nd quarter. BlackRock Inc. now owns 4,391,404 shares of the medical device company’s stock worth $321,232,000 after buying an additional 230,542 shares in the last quarter. Finally, Brown Advisory Inc. grew its holdings in DexCom by 57.2% in the 3rd quarter. Brown Advisory Inc. now owns 4,165,522 shares of the medical device company’s stock worth $203,798,000 after buying an additional 1,515,134 shares in the last quarter.
DexCom (NASDAQ:DXCM) opened at $56.75 on Friday. The company has a quick ratio of 5.50, a current ratio of 5.86 and a debt-to-equity ratio of 0.84. DexCom has a one year low of $42.62 and a one year high of $88.80. The company has a market capitalization of $4,931.75, a PE ratio of -99.56 and a beta of 0.31.
COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Expect DexCom, Inc. (DXCM) to Post $0.03 Earnings Per Share” was first reported by Markets Daily and is owned by of Markets Daily. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.themarketsdaily.com/2018/01/14/zacks-analysts-expect-dexcom-inc-dxcm-to-post-0-03-earnings-per-share.html.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.